XML 14 R4.htm IDEA: XBRL DOCUMENT v3.20.2
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Development revenues:        
Government contracts and other   $ 4,771 $ 303 $ 5,810
Operating expenses:        
Research and development $ 336 921 1,604 3,636
Sales and marketing 104 94 319 305
General and administrative 956 1,076 3,788 3,313
Total operating expenses 1,396 2,091 6,492 7,254
Operating income (loss) (1,396) 2,680 (6,189) (1,444)
Other income (expense):        
Interest income 2 6 47 20
Interest expense (253) (366) (854) (1,477)
Change in fair value of warrants (81) (561) 2,342 (69)
Warrant issuance cost   (1,233)   (1,233)
Total other income (expense) (332) (2,154) 1,535 (2,759)
Income (Loss) from continuing operations (1,728) 526 (4,654) (4,203)
Loss from discontinued operations       (7,568)
Net income (loss) (1,728) 526 (4,654) (11,771)
Income (Loss) from continuing operations (1,728) 526 (4,654) (4,203)
Beneficial conversion feature for convertible preferred stock   (554)   (554)
Net loss allocable to common stockholders - continuing operations $ (1,728) $ (28) $ (4,654) (4,757)
Net loss allocable to common stockholders - discontinued operations       $ (7,568)
Basic and diluted net loss per share attributable to common stockholders - continuing operations $ (0.39) $ (0.03) $ (1.13) $ (8.78)
Basic and diluted net loss per share attributable to common stockholders - discontinued operations       (13.97)
Net loss per share, basic and diluted $ (0.39) $ (0.03) $ (1.13) $ (22.75)
Basic and diluted weighted average shares used in calculating net loss per share attributable to common stockholders 4,402,221 826,548 4,113,928 541,777
In Process Research and Development [Member] | Nano Tx Therapeutics [Member]        
Operating expenses:        
Research and development     $ 781